Recent advances in the development of farnesoid X receptor agonists
about
Current Management of Alcoholic Hepatitis and Future TherapiesThe enteric microbiome in hepatobiliary health and diseaseBile Acid Metabolism and Signaling in Cholestasis, Inflammation, and CancerRecent advances in the diagnosis and treatment of primary biliary cholangitis.Gut Microbiota and Host Reaction in Liver DiseasesRelevance of FXR-p62/SQSTM1 pathway for survival and protection of mouse hepatocytes and liver, especially with steatosisObeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis.Pharmacology of bile acid receptors: Evolution of bile acids from simple detergents to complex signaling molecules.Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease.Early primary biliary cholangitis is characterised by brain abnormalities on cerebral magnetic resonance imaging.Activation of FXR protects against renal fibrosis via suppressing Smad3 expression.The transcription cofactor CRTC1 protects from aberrant hepatic lipid accumulation.Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.Determination of 7α-OH cholesterol by LC-MS/MS: Application in assessing the activity of CYP7A1 in cholestatic minipigs.Blinded evaluation of farnesoid X receptor (FXR) ligands binding using molecular docking and free energy calculations.Performance of HADDOCK and a simple contact-based protein-ligand binding affinity predictor in the D3R Grand Challenge 2.Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich-cultured human hepatocytes.FXR-Gankyrin axis is involved in development of pediatric liver cancer.Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview.Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis.Targeting the Farnesoid X Receptor in Patients With Cholestatic Liver Disease.The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway.Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease.Treatment options for alcoholic and non-alcoholic fatty liver disease: A review.Drugs and Targets in Fibrosis.Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis.Remote Sensing between Liver and Intestine: Importance of Microbial Metabolites.The farnesoid-X-receptor in myeloid cells controls CNS autoimmunity in an IL-10-dependent fashion.Editor's Highlight: Farnesoid X Receptor Protects Against Low-Dose Carbon Tetrachloride-Induced Liver Injury Through the Taurocholate-JNK Pathway.Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis.Obeticholic Acid: A Farnesoid X Receptor Agonist for Primary Biliary Cholangitis.Primary Sclerosing Cholangitis, Part 1: Epidemiology, Etiopathogenesis, Clinical Features, and Treatment.Obesity and nonalcoholic fatty liver disease: current perspectivesDysregulated bile acid synthesis and dysbiosis are implicated in Western diet-induced systemic inflammation, microglial activation, and reduced neuroplasticityNew Aspects of Lipotoxicity in Nonalcoholic SteatohepatitisSynbiotics Bifidobacterium infantis and milk oligosaccharides are effective in reversing cancer-prone nonalcoholic steatohepatitis using western diet-fed FXR knockout mouse modelsBile acid metabolism and signaling in liver disease and therapyBile Acid Synthesis: From Nature to the Chemical Modification and Synthesis and Their Applications as Drugs and NutrientsFXR and TGR5 Agonists Ameliorate Liver Injury, Steatosis, and Inflammation After Binge or Prolonged Alcohol Feeding in MiceA nonalcoholic fatty liver disease model in human induced pluripotent stem cell-derived hepatocytes, created by endoplasmic reticulum stress-induced steatosis
P2860
Q26746544-ED1904AD-F3F8-4E83-89A4-E9D99CD9125AQ26777426-235A3630-3036-4741-A8FE-A8EB32874662Q26800206-9873E48D-BDCC-4A8D-9546-7023A492E0E9Q28076353-1D692177-3475-4DF4-BFB9-21B9899B2E71Q28083295-14DB6017-8674-4C32-B30E-644A666EFF39Q36249266-1FC6E6C0-BDDB-461D-8CF7-5369A10001FEQ36598778-6FCA507F-23F7-4BEA-A87E-746D0EBB9B15Q36987335-EBFDCC73-B858-4309-8445-E782E58BC1DDQ37062751-2E741D2E-50EC-4341-BDE0-F83B84203601Q37371069-DAB9491F-13E3-4604-AC73-A8A6502B0A12Q37419118-C2FDEFF4-DEE3-416C-A89C-36F226E0BFD3Q37424899-49123E6C-3FD1-4863-B66B-B71DED1CD202Q37538343-45790A55-C301-4E71-BACB-0E5C1C58E10AQ37711000-45DC14AD-32A7-461E-B4AC-E2B500B25D54Q38597033-738B8D42-2B53-4BC0-B4A0-D541BB99810DQ38613029-882F1424-CF22-4B90-931B-B596186D1EFAQ38626000-EFE6F571-216A-4DE7-BEE6-D1CFCFEBD325Q38768973-D05EAB39-5222-4E4F-88E4-3D4855933C5CQ38782562-8F004CE6-51EF-4CBD-A4BC-BC256690BA00Q38802973-BB910EF8-31C5-41A8-8D04-E520B03B383CQ41862942-BD709662-7320-4076-BDE6-9A309359C168Q42053662-18F900DB-B48B-40BC-A1FC-6B75C60E93F9Q42369256-A0F11CD6-40A5-48F4-8ADF-D916D7D3D155Q42695159-F0319E23-7727-46AF-B3E1-9E444D2D9547Q47119118-505230CD-AEB1-4D53-AC80-F6429640A97BQ47668921-70D7067D-3DE1-4677-8290-3B05BE6BE075Q49569061-DF6E53A4-441B-4865-B91A-13D4C9E71388Q50788241-27BE3EDB-8689-454F-B6F9-385DA2B2501AQ51000997-BE359EF1-7993-478E-A96C-8D8B6B02B77FQ52582202-4A136966-7B1B-45A2-BC37-F485924BE1ADQ55165714-6E54C452-BE02-44FE-9C9B-D6DED47D7B98Q55497458-885CC84B-EA4D-41BA-92AE-3F38FCA07CB3Q57069715-857E140C-D788-43E2-8BCC-2CD511A56659Q57101020-6408D1D7-BD1E-4865-9A72-F692B207EFE3Q57114860-FC6FFECC-FC09-4E27-A17F-37DF391EF8B0Q57115983-2AC9A3CE-A2DD-4381-94DF-C62A05402817Q57128767-131CDED1-80E4-4472-BEAD-07F72754F83FQ57492155-A2B34FB6-1022-441A-B3F5-09BA960FD824Q58562856-43D76945-C8EA-427A-B895-D657DD696FC0Q58697388-A06360BD-7E77-4EEE-B7C4-D8596B0A8A7D
P2860
Recent advances in the development of farnesoid X receptor agonists
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Recent advances in the development of farnesoid X receptor agonists
@ast
Recent advances in the development of farnesoid X receptor agonists
@en
Recent advances in the development of farnesoid X receptor agonists
@nl
type
label
Recent advances in the development of farnesoid X receptor agonists
@ast
Recent advances in the development of farnesoid X receptor agonists
@en
Recent advances in the development of farnesoid X receptor agonists
@nl
prefLabel
Recent advances in the development of farnesoid X receptor agonists
@ast
Recent advances in the development of farnesoid X receptor agonists
@en
Recent advances in the development of farnesoid X receptor agonists
@nl
P2093
P2860
P1476
Recent advances in the development of farnesoid X receptor agonists
@en
P2093
Ahmad H Ali
Elizabeth J Carey
Keith D Lindor
P2860
P356
10.3978/J.ISSN.2305-5839.2014.12.06
P577
2015-01-01T00:00:00Z